2cureX Q4’21: Ready for the Commercial Phase - Redeye

Redeye comments on 2cureX’s Q4’21 report. It has been an eventful quarter for 2cureX, including the launch of its new test for patients with mCRC in 1st line (IndiTreat Start), the signing of several new distribution agreements as well as the first IndiTreat order. We continue to see an interesting 2022 ahead and reiterate our Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/834682/2curex-q421-ready-for-the-commercial-phase?utm_source=finwire&utm_medium=RSS